Contribute Try STAT+ Today

In addition to the most visible effects of Covid-19 — tragic deaths, lingering illness, economic turmoil, and more — the pandemic is affecting much that is out of the spotlight. One is research on the so-called rare and ultra-rare diseases that affect an estimated 300 million people around the world.

One of us (S.K.R.) has a 2-year-old boy, Raghav, with an ultra-rare disease. He is just one of nine kids in the world identified so far with a disease caused by a mutation in the glutathione peroxidase 4 (GPX4) gene. It causes extremely low muscle tone, difficulty eating, problems seeing and hearing, and abnormalities in the spine, pelvis, and long bones. But Raghav is lucky: Most babies born with this disease die shortly after birth.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.